Literature DB >> 21721946

The role of MeCP2 in the brain.

Jacky Guy1, Hélène Cheval, Jim Selfridge, Adrian Bird.   

Abstract

Methyl-CpG binding protein 2 (MeCP2) was first identified in 1992 as a protein that binds specifically to methylated DNA. Mutations in the MECP2 gene were later found to be the cause of an autism spectrum disorder, Rett syndrome. Despite almost 20 years of research into the molecular mechanisms of MeCP2 function, many questions are yet to be answered conclusively. This review considers several key questions and attempts to evaluate the current state of evidence. For example, is MeCP2 just a methyl-CpG binding protein? Is it a multifunctional protein or primarily a transcriptional repressor? We also consider whether MeCP2, as a chromosome-binding protein, acts at specific sites within the genome or more globally, and in which cell types it is functionally important. Finally, we consider two alternative views of MeCP2 in the brain: as a regulator of brain development or as a factor that helps maintain neuronal/glial function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21721946     DOI: 10.1146/annurev-cellbio-092910-154121

Source DB:  PubMed          Journal:  Annu Rev Cell Dev Biol        ISSN: 1081-0706            Impact factor:   13.827


  204 in total

Review 1.  Excitatory/Inhibitory Balance and Circuit Homeostasis in Autism Spectrum Disorders.

Authors:  Sacha B Nelson; Vera Valakh
Journal:  Neuron       Date:  2015-08-19       Impact factor: 17.173

Review 2.  From the genetic architecture to synaptic plasticity in autism spectrum disorder.

Authors:  Thomas Bourgeron
Journal:  Nat Rev Neurosci       Date:  2015-09       Impact factor: 34.870

3.  The stress oncoprotein LEDGF/p75 interacts with the methyl CpG binding protein MeCP2 and influences its transcriptional activity.

Authors:  Lai Sum Leoh; Bart van Heertum; Jan De Rijck; Maria Filippova; Leslimar Rios-Colon; Anamika Basu; Shannalee R Martinez; Sandy S Tungteakkhun; Valeri Filippov; Frauke Christ; Marino De Leon; Zeger Debyser; Carlos A Casiano
Journal:  Mol Cancer Res       Date:  2012-01-24       Impact factor: 5.852

4.  Regulation of brain-derived neurotrophic factor expression in neurons.

Authors:  Fei Zheng; Xianju Zhou; Changjong Moon; Hongbing Wang
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-12-26

5.  Loss of MeCP2 from forebrain excitatory neurons leads to cortical hyperexcitation and seizures.

Authors:  Wen Zhang; Matthew Peterson; Barbara Beyer; Wayne N Frankel; Zhong-wei Zhang
Journal:  J Neurosci       Date:  2014-02-12       Impact factor: 6.167

6.  DNA Methylation program in normal and alcohol-induced thinning cortex.

Authors:  Nail Can Öztürk; Marisol Resendiz; Hakan Öztürk; Feng C Zhou
Journal:  Alcohol       Date:  2017-02-20       Impact factor: 2.405

7.  Overexpression of methyl-CpG binding protein 2 impairs T(H)1 responses.

Authors:  Tianshu Yang; Melissa B Ramocki; Jeffrey L Neul; Wen Lu; Luz Roberts; John Knight; Christopher S Ward; Huda Y Zoghbi; Farrah Kheradmand; David B Corry
Journal:  Sci Transl Med       Date:  2012-12-05       Impact factor: 17.956

8.  By hook or by crook: multifaceted DNA-binding properties of MeCP2.

Authors:  Jaehoon Shin; Guo-Li Ming; Hongjun Song
Journal:  Cell       Date:  2013-02-28       Impact factor: 41.582

9.  DNA methylation in the gene body influences MeCP2-mediated gene repression.

Authors:  Benyam Kinde; Dennis Y Wu; Michael E Greenberg; Harrison W Gabel
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-13       Impact factor: 11.205

10.  Pharmacological stimulation of the brain serotonin receptor 7 as a novel therapeutic approach for Rett syndrome.

Authors:  Bianca De Filippis; Paola Nativio; Alessia Fabbri; Laura Ricceri; Walter Adriani; Enza Lacivita; Marcello Leopoldo; Francesca Passarelli; Andrea Fuso; Giovanni Laviola
Journal:  Neuropsychopharmacology       Date:  2014-05-09       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.